Gland Pharma Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 2000% at ₹20/Share	11-Aug-2026	11-Aug-2026
DividendsFinal Dividend of 1800% at ₹18/Share	14-Aug-2025	14-Aug-2025

Mutual Fund Holder	Jul 26 Shares held	Aug 26 Shares held
HDFC Mid Cap Fund - Regular Plan - Growth	60.68 Lac	60.68 Lac no change
SBI Large & Midcap Fund - Regular Plan - IDCW	31.70 Lac	31.87 Lac (0.52%)
Nippon India Growth Mid Cap Fund - Growth Option	28.00 Lac	28.00 Lac no change
Mirae Asset Large & Midcap Fund - Regular Plan - Growth	24.55 Lac	19.55 Lac (20.38%)
Nippon India Small Cap Fund - Growth	18.32 Lac	18.32 Lac no change

Shashank Gupta

14 Sep • 11:26 PM · SEBI-Registered Analyst

Gland Pharma to Acquire Its US Subsidiary

GLAND

Gland Pharma Limited has approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd., another wholly owned subsidiary of the company. The transaction, approved by the Board on September 13, 2026, involves a cash consideration of US$501,208. Following completion, Gland Pharma USA will become a direct wholly owned subsidiary of Gland Pharma, instead of remaining a step-down subsidiary. The primary objective of the transaction is to simplify Gland Pharma's corporate structure by removing multiple layers of ownership. The company has stated that the acquisition is not expected to have any material impact on its business or operations. The transaction is classified as a related-party transaction and will be conducted on an arm's-length basis, with the consideration determined by an independent valuer. The required approvals from the Audit Committee and Board have been obtained. Gland Pharma USA was incorporated in March 2022 and operates in the pharmaceutical sector, with its principal activity being the marketing and distribution of pharmaceutical products in the United States. The US subsidiary reported turnover of approximately US$87,342 in FY25, compared with US$483,808 in FY24, while it reported nil turnover in FY26. Gland Pharma expects to complete the acquisition by October 31, 2026.

Kumar Satyam

14 Sep • 7:16 PM · SEBI-Registered Analyst

Gland Pharma to Make US Arm Direct Wholly-Owned Subsidiary

Gland Pharma will acquire a 100% stake in Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd. for a cash consideration of $501,208, simplifying its corporate structure. Key Highlights • Gland Pharma will acquire 100% equity of Gland Pharma USA Inc. • Consideration: $501,208, payable in cash. • Following the transaction, Gland Pharma USA will become a direct wholly-owned subsidiary of Gland Pharma. • The US entity is engaged in the marketing and distribution of pharmaceutical products in the United States. • Turnover stood at $87,342 in FY25, compared with $483,808 in FY24, while FY26 turnover was nil. • The acquisition is expected to be completed by October 31, 2026. Why It Matters This is primarily a corporate restructuring rather than an external acquisition, as Gland Pharma USA is being acquired from another group entity. The transaction simplifies the ownership structure by bringing the US marketing and distribution entity directly under Gland Pharma. Given the relatively small consideration and nil FY26 turnover of the US entity, the immediate financial impact appears limited. The key significance is the simplification of Gland Pharma’s US corporate structure.

GLAND

Chahat Aggrawal

13 Sep • 9:36 PM · SEBI-Registered Analyst

Gland Pharma Pays ₹1.40 Lakh Penalty Imposed

GLAND

has paid a combined penalty of ₹1.40 lakh to NSE and BSE in connection with a technical compliance breach under SEBI LODR regulations concerning the appointment of an independent director aged over 75 years. The company settled the full penalty amount suo motu, taking the step to ensure timely closure of the matter. The penalty relates to regulatory compliance requirements governing the appointment of independent directors and does not represent a material financial impact for the company. The development highlights the importance of adhering to prescribed corporate governance and listing regulations. Investors will continue to monitor regulatory disclosures and compliance-related developments at the pharmaceutical company as it maintains its governance and reporting obligations.

Akhilesh Jat SEBI RA

6 Sep • 11:11 PM · SEBI-Registered Analyst

Gland Pharma Holds Near Highs Despite Fosun Stake Sale

Gland Pharma gained 0.84% on September 4 despite a major Fosun stake sale, with the stock trading close to its 52-week high. Gland Pharma Ltd. (NSE:

GLAND

) remained resilient on September 4, 2026, closing 0.84% higher despite significant promoter stake-sale activity. The stock ended the session just 3.53% below its 52-week and nearly three-year high of ₹3,039.80, reflecting continued investor interest. In pre-open market activity, Fosun Pharma Industrial was reportedly looking to sell around 5% of its stake in Gland Pharma through a block deal valued at approximately ₹2,279.5 crore. The reported floor price for the transaction was ₹2,763 per share. Subsequent reports indicated that Fosun Pharma ultimately sold a 4.5% stake for around ₹2,121.5 crore. The shares were reportedly acquired by 11 institutional investors at a price of ₹2,826.60 per share, highlighting strong institutional demand despite the large transaction size. The stake sale marks a notable change in the company's ownership structure and is expected to improve the stock's free float. Market participants will closely monitor whether the entry of institutional investors supports liquidity and sustains the stock's upward momentum. With Gland Pharma trading near its recent highs, future earnings performance and business developments are likely to remain key factors influencing investor sentiment. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

Ashish Kumar

6 Sep • 7:46 PM · SEBI-Registered Analyst

Fosun Pharma Offloads 4.5% Stake in Gland Pharma

Chinese pharmaceutical major Fosun Pharma has sold a 4.5–4.55% stake in Hyderabad-based !GLAND Pharma for ₹2,121.5 crore through block deals on September 4, 2026. Fosun Pharma Industrial Pte Ltd, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical and the promoter of Gland Pharma, offloaded 75.05 lakh shares (approximately 4.55% of the company) across multiple tranches. The shares changed hands at an average price of ₹2,826.60 each. The sale reduced Fosun’s holding from 51.77% (as of June 2026) to 47.22%, taking it below the 50% mark for the first time. Gland Pharma, a specialist in generic injectables and This marks Fosun’s second significant stake sale in the company in just over two years, following a 6% divestment in June 2024.

Saksham Sharma

6 Sep • 11:57 AM · SEBI-Registered Analyst

Cohance Lifesciences Receives 4 FDA Form 483 Observations

COHANCE

Lifesciences received four FDA Form 483 observations following a plant inspection. This is worth reading directly alongside the Gland Pharma inspection we covered recently, that facility received zero observations from the FDA. Here's what actually happens on this other side of the outcome. 1. A Form 483 is a list of specific deficiencies inspectors observed, not a final penalty. It's issued at the end of an inspection when investigators identify conditions that may violate FDA regulations. Receiving one isn't the end of the process, it's the start of a formal response cycle. 2. The company now has to respond in writing, typically within 15 business days. Cohance would need to submit a corrective action plan addressing each of the four observations, explaining what will be fixed and by when. The FDA then reviews that response before deciding on further action. 3. Not every Form 483 leads to serious consequences. Outcomes range widely, some observations get resolved with minor procedural fixes and no further action, while more serious or repeated issues can escalate to a Warning Letter or import restrictions. Four observations, without knowing their specific severity, doesn't by itself tell you which outcome is likely here. An inspection with observations creates a period of genuine uncertainty, the business isn't necessarily disrupted yet, but the range of possible outcomes is now much wider than it was for a facility with a clean result. The takeaway: Not all FDA inspection outcomes are equal, and not all Form 483s are equally serious. The real story here plays out over the coming weeks, in Cohance's written response and the FDA's reaction to it, not in the observation count alone.

Gland Pharma Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Gland Pharma Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Gland Pharma Ltd.?

What is the market cap of Gland Pharma Ltd.?

Should I buy Gland Pharma Ltd. stock now?

What is the 52 week high and low of Gland Pharma Ltd.?

Is the Gland Pharma Ltd. stock good to buy?

Is Gland Pharma Ltd. a good buy for the long term?

Is Gland Pharma Ltd. overvalued or undervalued?

What is the PE and PB ratio of Gland Pharma Ltd.?